Dr Ola Landgren speaks to ecancer about a recent study presented at ASH 2020 regarding the paper; weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma: final results from a clinical and correlative phase 2 study.
He says bortezomib, lenalidomide and dexamethasone (VRd) is considered a standard of care combination therapy for newly diagnosed multiple myeloma patients and that prior studies show that ~25% of patients treated with 8 cycles of VRd achieve minimal residual disease (MRD) negativity.
He then explains the methods used in this paper to evaluate the efficacy of this combination therapy against multiple myeloma and then moves on to talk about some of the key results obtained from this study.
In the end, he talks about the future of this clinical trial and the impact it can have on MM research and treatment.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.